Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;34(1):1347-1367.
doi: 10.1080/14756366.2019.1642883.

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition

Affiliations

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition

Salwa Elmeligie et al. J Enzyme Inhib Med Chem. 2019 Dec.

Abstract

In the designed compounds, either a biarylamide or biarylurea moiety or an N-substituted piperazine motif was linked to position 1 of the phthalazine core. The anti-proliferative activity of the synthesised compounds revealed that eight compounds (6b, 6e, 7b, 13a, 13c, 16a, 16d and 17a) exhibited excellent broad spectrum cytotoxic activity in NCI 5-log dose assays against the full 60 cell panel with GI50 values ranging from 0.15 to 8.41 µM. Moreover, the enzymatic assessment of the synthesised compounds against VEGFR-2 tyrosine kinase showed the significant inhibitory activities of the biarylureas (12b, 12c and 13c) with IC50s of 4.4, 2.7 and 2.5 μM, respectively, and with 79.83, 72.58 and 71.6% inhibition of HUVEC at 10 μM, respectively. Additionally, compounds (7b, 13c and 16a) were found to induce cell cycle arrest at S phase boundary. Compound 7b triggered a concurrent increase in cleaved caspase-3 expression level, indicating the apoptotic-induced cell death.

Keywords: Substituted phthalazines; VEGFR-2 kinase inhibitors; anti-proliferative; apoptosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structures of some known VEGFR-2 kinase inhibitors.
Figure 2.
Figure 2.
Strategy for the design of the target compounds.
Scheme 1.
Scheme 1.
(a) Reagents and conditions: (i) dioxane, rt, 1 h. (b) Reagents and conditions: (i) NH2NH2 99%, propanol, 2 h (ii) POCl3, reflux 70 °C, 2 h (iii) p-phenylenediamine, butanol, 110 °C, 1 h, (iv) benzoyl chlorides, acetonitile, triethylamine, 6 h (v) arylisocyanates, DMF, reflux, 8 h, (vi) 1a–c, Cs2CO3, acetonitrile, reflux, 6 h, (vii) piperazines, K2CO3, KI, ethanol, reflux, 3 h.
Scheme 2.
Scheme 2.
Reagents and conditions: (i) NH2NH2 acetic, reflux, 3 h (ii) POCl3, reflux 110 °C, 1 h (iii) p-phenylenediamine, butanol, 110 °C, 1 h, (iv) phenylisocyanates, DMF, reflux, 8–10 h, (v) 1a–c, Cs2CO3, acetonitrile, reflux, 6–8 h.
Scheme 3.
Scheme 3.
Reagents and conditions: (i) aniline derivatives, butanol, K2CO3, KI, reflux, 3 h (ii) NBS, dibenzoyl chloride, reflux, 24 h (iii) aniline derivatives, acetone, K2CO3, KI, reflux, 6 h (iv) phenol derivatives, NaH, acetone, reflux, 8 h.
Figure 3.
Figure 3.
IC50 curves for compounds (6c, 12b, 12c and 13c) against the VEGFR-2 kinase.
Figure 4.
Figure 4.
The bar graphs showing the HUVECs growth percentage after treatment with the target compounds.
Figure 5.
Figure 5.
Effect of compound 7b on DNA-ploidy flow cytometric analysis of MCF7 cells. MCF-7cells were treated with DMSO 0.01% or compound 7b at its GI50 (0.32 µM), for 24 h and 48 h, and the harvested cells were subjected to Cell-cycle analysis using a FACS Calibur flow cytometer (A,B and C). Bar chart shows percentage of MCF7 cells at each phase of cell cycle in DMSO and compound 7b treated cells.
Figure 6.
Figure 6.
Effect of compound 13c on DNA-ploidy flow cytometric analysis of MCF7 cells. MCF-7cells were treated with DMSO 0.01% or compound 13c at its GI50 (0.57 µM), for 24 h and 48 h, and the harvested cells were subjected to cell-cycle analysis using a FACS Calibur flow cytometer (A, B and C). Bar chart shows percentage of MCF7 cells at each phase of cell cycle in DMSO and compound 13c treated cells.
Figure 7.
Figure 7.
Effect of compound 16a on DNA-ploidy flow cytometric analysis of HCT-116 cells. HCT-116 cells were treated with DMSO 0.01% or compound 16a at its GI50 (1.20 µM), for 24 h and 48 h, and the harvested cells were subjected to Cell-cycle analysis using a FACS Calibur flow cytometer (A,B and C). Bar chart shows percentage of HCT-116 cells at each phase of cell cycle in DMSO and compound 16a treated cells.
Figure 8.
Figure 8.
Effect of compound 7b treatment on induction of apoptosis. MCF-7 cells were treated with DMSO 0.01% or compound 7b at its GI50 (0.32 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.
Figure 9.
Figure 9.
Effect of compound 13c treatment on induction of apoptosis. MCF-7 cells were treated with DMSO 0.01% or compound 13c at its GI50(0.57 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.
Figure 10.
Figure 10.
Effect of compound 16a treatment on induction of apoptosis. HCT-116 cells were treated with DMSO 0.01% or compound 16a at its GI50(1.20 µM) for 24 or 48h, the harvested cells were stained with Annexin V-FITC apoptosis detection kit and Analyzed on a Flow cytometer.
Figure 11.
Figure 11.
Effect of compound 7b on the cellular and nuclear morphology. MCF-7 cells were seeded on cover slips in a 6- well tissue culture plate, the cells then were treated with DMSO 0.01% or compound 7b (0.32 µM) for 24 or 48h, the cells were imaged with the light microscope to examine the cellular morphology (A) or stained with the nuclear stain Dapi to study the nuclear morphology using fluorescence microscope (B).
Figure 12.
Figure 12.
Effect of compound 7 b on cleaved caspase-3 protein expression. MCF-7 cells were seeded on cover slips in a 6-well tissue culture plate, the cells then were treated with DMSO 0.01% or compound 7b at its GI50(0.32 µM) for 48h, the cells were then permiabilised, fixed, blocked and stained with the primary and secondary antibodies, the nuclear stain Dapi was used as a counter stain. The image were taken using a fluorescence microscope.
Figure 13.
Figure 13.
Overlay of the best-scored docking poses of some relevant compounds on the co-crystallised ligand Sorafenib (cyan sticks) in the binding site of VEGFR2 (PDB: 4ASD):. (A) The docking pose of 6c as magenta sticks, (B) the docking poses of 12b and 12c as yellow and purple sticks, respectively, and (C) the docking pose of 13c as gold sticks. (D) The docking poses of 12c and 13c at a different perspective of the binding site showing the extended hydrophobic contact of the chloro and trifluoromethyl phenyl moiety with the side chains of PHE-918 and LEU-840. The yellow dashed-lines represent the polar contacts (H-bonding interactions). Non-polar hydrogen atoms were omitted for clarity. All presented docking poses are the best-scored by AutoDock Vina.

Similar articles

Cited by

References

    1. Zhang YS, Liu Y, Chen D, et al. . Synthesis and antitumor activities of novel 1,4-disubstituted phthalazine derivatives. Eur. J. Med. Chem 2010;45:3504–10. - PubMed
    1. Imramovský A, Jorda R, Pauk K, et al. . Substituted 2-hydroxy-N-(arylalkyl)benzamides induce apoptosis in cancer cell lines. Eur J Med Chem 2013;68:253–9. - PubMed
    1. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ 2001;322:1536–8. - PMC - PubMed
    1. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39. - PubMed
    1. Cortes E, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 2013;50:271–83. - PMC - PubMed

MeSH terms